Changeflow GovPing Pharma & Healthcare First-in-human SRP-1005 Huntington's Disease Ph...
Routine Notice Added Final

First-in-human SRP-1005 Huntington's Disease Phase 1 Trial

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH ClinicalTrials.gov registered a first-in-human Phase 1 trial (NCT07536061) studying SRP-1005, an investigational treatment for Huntington's Disease. The multi-center trial will evaluate the safety and tolerability of SRP-1005 versus placebo in participants with Huntington's Disease. The trial has an anticipated start date of April 17, 2026.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

NIH registered a new first-in-human Phase 1 clinical trial on ClinicalTrials.gov for SRP-1005, an investigational drug for Huntington's Disease. The trial NCT07536061 is classified as Phase 1 and will study the effects of SRP-1005 against placebo in multiple centers.

For pharmaceutical sponsors and clinical investigators, this registration signals an emerging development program in Huntington's Disease. Patients and advocacy groups gain visibility into upcoming clinical research. The trial represents early-stage development with no immediate compliance obligations for external parties.

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease

Phase 1 NCT07536061 Kind: PHASE1 Apr 17, 2026

Abstract

This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).

Conditions: Huntington's Disease

Interventions: SRP-1005, Placebo

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 17th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07536061

Who this affects

Applies to
Pharmaceutical companies Clinical investigators
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Clinical trial registration Pharmaceutical research
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Topics
Healthcare Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!